Litigants Weigh Appeal To Australian Court Ruling Over Myriad Genetics’ Rights For BRCA1 Gene
This article was originally published in PharmAsia News
Executive Summary
Australian Federal Court rules in Myriad Genetics favor that BRCA1 gene can be patented, but whether the ruling will be upheld is another story.
You may also be interested in...
Myriad Gene Patent Case May Go To Supreme Court After Federal Circuit Backs Firm
A Federal Circuit panel again rules that Myriad Genetics’ patents covering BRCA genes isolated from the body are patent-eligible; the ACLU may request review by the full court or file a petition with the Supreme Court.
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.
INTERVIEW: Business Is Personal For Avita CEO Kelliher
As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.